Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
W. Wang
Institutions:
Tianjin Medical University Cancer Institute and Hospital,
University of California San Diego,
Moores Cancer Center
Observed institutions:
Tianjin Medical University Cancer Institute and Hospital,
University of California San Diego,
Moores Cancer Center
ORCID:
0009-0005-7979-1021
Observed ORCID:
0009-0005-7979-1021
OpenAlex ID:
A5079340511
1494P Pooled efficacy and safety outcomes with tremelimumab plus durvalumab in participants (pts) with unresectable hepatocellular carcinoma (uHCC) from the combined China extension and global cohorts in the phase III HIMALAYA study
2025
·
B. Sangro
, S. Qin
, et al.
·
Annals of Oncology
·
6
WITHDRAWN: 679P Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: A retrospective study
2025
·
W. Wang
, B. Wang
, et al.
·
Annals of Oncology
1303 Preoperative chemoradiation with capecitabine for rectal cancer in elderly patients: A phase I trial
2015
·
W. Liu
, Y. Tang
, et al.
·
European Journal of Cancer
Show more works
View as search
Works count:
3
Citation count:
6
H-index:
1
I10-index:
Year
Topic
Type